Latest Insider Transactions at Veracyte, Inc. (VCYT)
This section provides a real-time view of insider transactions for Veracyte, Inc. (VCYT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of VERACYTE, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of VERACYTE, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 16
2023
|
Karin Eastham Director |
BUY
Exercise of conversion of derivative security
|
Direct |
18,750
+30.76%
|
$225,000
$12.12 P/Share
|
|
Mar 15
2023
|
Bonnie H Anderson Director |
SELL
Open market or private sale
|
Direct |
34,000
-38.65%
|
$748,000
$22.76 P/Share
|
|
Mar 15
2023
|
Bonnie H Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
34,000
+27.88%
|
$170,000
$5.61 P/Share
|
|
Mar 06
2023
|
Jonathan Wygant VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,868
+23.66%
|
-
|
|
Mar 06
2023
|
Annie Mc Guire SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
23,413
+29.93%
|
-
|
|
Mar 06
2023
|
Marc Stapley Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
78,044
+25.26%
|
-
|
|
Mar 06
2023
|
Rebecca Chambers Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,014
+21.16%
|
-
|
|
Mar 02
2023
|
Annie Mc Guire SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
2,152
-6.41%
|
$51,648
$24.1 P/Share
|
|
Mar 02
2023
|
Jonathan Wygant VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,224
-5.84%
|
$29,376
$24.1 P/Share
|
|
Mar 02
2023
|
Bonnie H Anderson Director |
SELL
Payment of exercise price or tax liability
|
Direct |
8,994
-14.29%
|
$215,856
$24.1 P/Share
|
|
Mar 02
2023
|
Marc Stapley Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,029
-3.79%
|
$144,696
$24.1 P/Share
|
|
Mar 02
2023
|
Rebecca Chambers Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,726
-3.7%
|
$65,424
$24.1 P/Share
|
|
Feb 28
2023
|
Karin Eastham Director |
SELL
Open market or private sale
|
Direct |
10,000
-29.89%
|
$250,000
$25.0 P/Share
|
|
Feb 28
2023
|
Karin Eastham Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+23.01%
|
$120,000
$12.12 P/Share
|
|
Jan 17
2023
|
Bonnie H Anderson Director |
SELL
Open market or private sale
|
Direct |
34,000
-18.55%
|
$884,000
$26.47 P/Share
|
|
Jan 17
2023
|
Bonnie H Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
34,000
+25.96%
|
$170,000
$5.61 P/Share
|
|
Jan 11
2023
|
Bonnie H Anderson Director |
SELL
Open market or private sale
|
Direct |
63,247
-50.11%
|
$1,581,175
$25.13 P/Share
|
|
Jan 11
2023
|
Bonnie H Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
63,247
+33.38%
|
$885,458
$14.34 P/Share
|
|
Dec 14
2022
|
Evan/ Fa Jones Director |
SELL
Open market or private sale
|
Direct |
600
-1.18%
|
$18,000
$30.13 P/Share
|
|
Dec 13
2022
|
Evan/ Fa Jones Director |
SELL
Open market or private sale
|
Direct |
1,667
-1.6%
|
$51,677
$31.08 P/Share
|
|
Dec 06
2022
|
Giulia C Kennedy Chief Scientific & Med Officer |
SELL
Open market or private sale
|
Direct |
1,023
-1.53%
|
$27,621
$27.03 P/Share
|
|
Dec 02
2022
|
Bonnie H Anderson Director |
SELL
Payment of exercise price or tax liability
|
Direct |
2,042
-3.14%
|
$59,218
$29.14 P/Share
|
|
Dec 02
2022
|
Marc Stapley Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,012
-0.64%
|
$29,348
$29.14 P/Share
|
|
Dec 02
2022
|
Rebecca Chambers Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
735
-1.0%
|
$21,315
$29.14 P/Share
|
|
Dec 02
2022
|
Giulia C Kennedy Chief Scientific & Med Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,008
-1.48%
|
$29,232
$29.14 P/Share
|
|
Dec 01
2022
|
Bonnie H Anderson Director |
SELL
Open market or private sale
|
Direct |
80,000
-32.49%
|
$2,240,000
$28.21 P/Share
|
|
Dec 01
2022
|
Bonnie H Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
80,000
+23.72%
|
$720,000
$9.98 P/Share
|
|
Nov 11
2022
|
Giulia C Kennedy Chief Scientific & Med Officer |
SELL
Open market or private sale
|
Direct |
2
-0.0%
|
$58
$29.34 P/Share
|
|
Nov 11
2022
|
Giulia C Kennedy Chief Scientific & Med Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2
+0.0%
|
$28
$14.34 P/Share
|
|
Nov 11
2022
|
Evan/ Fa Jones Director |
SELL
Open market or private sale
|
Direct |
6,000
-5.14%
|
$180,000
$30.62 P/Share
|
|
Nov 04
2022
|
Giulia C Kennedy Chief Scientific & Med Officer |
SELL
Open market or private sale
|
Direct |
1,023
-1.48%
|
$25,575
$25.0 P/Share
|
|
Oct 13
2022
|
Bonnie H Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,088
+6.76%
|
$88,704
$8.96 P/Share
|
|
Sep 02
2022
|
Marc Stapley Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,012
-0.63%
|
$19,228
$19.18 P/Share
|
|
Sep 02
2022
|
Giulia C Kennedy Chief Scientific & Med Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,008
-1.44%
|
$19,152
$19.18 P/Share
|
|
Sep 02
2022
|
Rebecca Chambers Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,023
-3.94%
|
$57,437
$19.18 P/Share
|
|
Sep 02
2022
|
Bonnie H Anderson Director |
SELL
Payment of exercise price or tax liability
|
Direct |
2,042
-3.05%
|
$38,798
$19.18 P/Share
|
|
Aug 09
2022
|
Eliav Barr Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,721
+50.0%
|
-
|
|
Aug 08
2022
|
Bonnie H Anderson Director |
SELL
Open market or private sale
|
Indirect |
45,000
-14.9%
|
$1,215,000
$27.53 P/Share
|
|
Aug 05
2022
|
Giulia C Kennedy Chief Scientific & Med Officer |
SELL
Open market or private sale
|
Direct |
1,028
-1.45%
|
$26,728
$26.54 P/Share
|
|
Aug 05
2022
|
Giulia C Kennedy Chief Scientific & Med Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5
+0.0%
|
$35
$7.44 P/Share
|
|
Aug 05
2022
|
Giulia C Kennedy Chief Scientific & Med Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,702
+13.09%
|
-
|
|
Aug 05
2022
|
Bonnie H Anderson Director |
SELL
Open market or private sale
|
Indirect |
76,917
-32.82%
|
$2,076,759
$27.71 P/Share
|
|
Aug 05
2022
|
Rebecca Chambers Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,404
+21.81%
|
-
|
|
Aug 05
2022
|
Jonathan Wygant VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,561
+29.4%
|
-
|
|
Aug 05
2022
|
Annie Mc Guire SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
10,702
+24.18%
|
-
|
|
Jun 16
2022
|
Evan/ Fa Jones Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,731
+20.13%
|
-
|
|
Jun 16
2022
|
John L Bishop Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,731
+38.58%
|
-
|
|
Jun 16
2022
|
Muna Bhanji Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,731
+35.93%
|
-
|
|
Jun 16
2022
|
Karin Eastham Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,731
+38.58%
|
-
|
|
Jun 16
2022
|
Robert S Epstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,731
+38.58%
|
-
|